Vectura Share Discussion Threads

[rivaldo] 24/11/2016 15:09

...and the IC have upgraded to a Buy:



Conclusion:

"IC VIEW:

Significant newsflow is expected from partnered drugs currently in development and that brings the promise of more milestone payments. There's a lot to like about Vectura's own pipeline as well, and though development costs are expected to increase next year, the balance sheet is strong. Upgrade to buy."

[rivaldo] 24/11/2016 12:05

For non-subscribers, the Tempus article in the Times says Buy (bit of a generalist/uninformed article though, to say the least!):

Conclusion:

"On one analyst’s reading of future profits for the first full year of the merger, the shares sell on ten times’ earnings, which does not look challenging, although the numbers look somewhat premature. There is, inevitably, no dividend, but the company would appear to be in an interesting place and looks an intriguing long-term bet.

MY ADVICE Buy

WHY Shares are hard to value because of the amount of product still not on the market, but its chosen area of healthcare can only grow"

JP Morgan have a 230p target and are overweight on VEC:



And N+1 Singer say Buy with a 208p target:

[carpadium] 24/11/2016 11:56

Short term share price heavily dependent on Novartis, to a lesser extent santa effect and
NY tipsters. Big question is will they get a Christmas card from Glaxo this year?

[tcarter66208] 24/11/2016 08:32

165 close year

[cityfarmer] 24/11/2016 07:38

A bit of commentary from the Times:

[cityfarmer] 23/11/2016 16:56

Great article although Motley Fool was also a fan of SKP many years ago (as was I) we both got that wrong I agree with their article today let’s hope we (both) get it right this time – I am certainly in……R30;

[carpadium] 23/11/2016 16:35

Could Vectura Group plc grow to be a FTSE 100 company within 10 years?

[alexchry] 23/11/2016 13:50

There seems to be nothing new in the results and the presentation. Solid results today and jam tomorrow. The words well-positioned were used a few times in the presentation, I just hope this positioning leads to concrete results. Just as we were before the results, we are waiting for the Novartis marketing decision, the settlement of the litigation and the FDA decision in May.

[soundbuy] 23/11/2016 11:52

"Who knows how long it will take," Mr Ward-Lilley said when asked when the litigation might end. "We would have liked to have solved it directly with Glaxo, but that wasn't possible so we had to go down the litigation route."

The long haul it is then....?

[soundbuy] 23/11/2016 11:50

Drug maker Vectura hails 'step change' after Skypharma merger

[boadicea] 23/11/2016 09:19

We should probably be basing forward projections of revenue etc on the pro forma figures. Using those and the current shares in issue (rather than the weighted average used for the adjusted eps) I get a suggestion of 4.5p adjusted pro forma eps for the half year.
That looks pretty healthy to me for a company with strongly expanding revenue and should result in a relatively modest prospective p/e in the low or mid teens going forward. Therefore, plenty of room for upside from the current share price imho.

[diesel] 23/11/2016 08:42

Alex.., oh I know, but Fluti was and SKP was a revenue engine under full steam when hooked up with Vec, and that side seems to have stalled.

[alexchry] 23/11/2016 08:34

Diesel-there is a lot more to digest than in the SKP days and a lot more uncertainty to go with the opportunities. It will be interesting to see the analysts' take on the results after their briefing this morning.

[richtea1701] 23/11/2016 08:24

Market likes concept of 'step change' - might try and screw the new money later but generally looks to have noted transformational idea

[diesel] 23/11/2016 08:24

Not sure about the details, will read again and digest, Fluti for example seems to have gone backwards in the last qtr, and that's with a weakened £.

[alexchry] 23/11/2016 08:10

Verger-yes, it sounds pretty good but nothing we didn't know already although it's good to have reassurance so hopefully the share price will strengthen a little. Nothing significant about the litigation, I was hoping for something a bit more promising about that but it may be difficult to say much while talks are ongoing. One thing that caught my eye was the intention to takeover a company in the US, something that was mentioned in an interview recently. VEC have lots of things on the boil, if they all come to fruition in the next six months I'd expect to see the share price approaching 200p, here's hoping.

[edmate] 23/11/2016 08:09

I was very apprehensive before bell thismorning about the loss mentioned in the results. Market doesn't seem bothered. Previously priced in ?

[srichardson8] 23/11/2016 08:07

This could be the start of something big

[soundbuy] 23/11/2016 08:00

VEC Peel Hunt Buy 146.30 146.30 200.00 PT: 200.00 Reiterates

[soundbuy] 23/11/2016 07:44

FTSE opening call +29 - Vectura up 1-2%, United Utilities. unch, Thomas Cook up 2-3%, Paragon up 1-2%

[verger] 23/11/2016 07:39

James Ward-Lilley, Chief Executive Officer of Vectura:

"These strong results represent a step-change for Vectura following the merger with Skyepharma during the period. We have continued to see sustained momentum in recurring revenues from recently-launched inhaled products. Vectura now owns or is partnered with seven assets that are currently in Phase III development or under regulatory review and we have made substantial pipeline progress with our innovative and generic assets at both late and earlier stages. We are making excellent progress with the merger integration process including completing the portfolio review, adding new programmes and implementing the new organisation structure. We remain on course to at least deliver the identified synergy savings and look forward to strong financial performance and continued progress across our pipeline in the remainder of the year and beyond.

Vectura's unique breadth of device platforms, expertise in formulation and track record of delivering medicines to market means the Group is well placed to deliver significant further shareholder value capitalising upon changes in market dynamics, both as a potential partner for both generic and novel development programmes and through the future commercialisation of wholly-owned niche assets targeting specific patient populations."
Sounds pretty good to me.